Trial Profile

A Phase II Study of AB-16B5 Combined With Docetaxel in Previously Treated Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Sotevtamab (Primary)
Indications Adenocarcinoma; Adenosquamous carcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Alethia BioTherapeutics

Most Recent Events

04 Jun 2024 Interim results (data cutoff date: Feb 2023) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
17 Jan 2024 Status changed from active, no longer recruiting to completed.
14 Sep 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com